Ron Bose.jpg

Ron Bose, MD, PhD

Associate Professor
Department of Medicine
Oncology Division
Molecular Oncology
Department of Cell Biology & Physiology

Clinical Interests

  • Her2-positive breast cancer
  • Breast cancer

Research Interests

  • Her2/neu tyrosine kinase
  • Genomics of breast cancer
  • Use of proteomics to study breast cancer cell signaling


  • 314-747-9308 (tel)
  • 314-747-9320 (fax)
  • 4515 McKinley Research Building, Room 3310 (office)
  • Division of Oncology
    Campus Box 8076
    Washington University Medical School
    660 South Euclid Avenue
    St. Louis, MO 63110
  • Bose lab website


  • Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer
    Ma CX, Bose R, Gao F, Freedman RA, Telli ML, Kimmick G, Winer E, Naughton M, Goetz MP, Russell C, Tripathy D, Cobleigh M, Forero A, Pluard TJ, Anders C, Niravath PA, Thomas S, Anderson J, Bumb C, Banks KC, Lanman RB, Bryce R, Lalani AS, Pfeifer J, Hayes DF, Pegram M, Blackwell K, Bedard PL, Al-Kateb H, Ellis MJC
    Clin Cancer Res 2017 Oct 1;23(19):5687-5695
  • Analysis of somatic mutations across the kinome reveals loss-of-function mutations in multiple cancer types
    Kumar RD, Bose R
    Sci Rep 2017 Jul 25;7(1):6418
  • Efficient sortase-mediated N-terminal labeling of TEV protease cleaved recombinant proteins
    Sarpong K, Bose R
    Anal Biochem 2017 Mar 15;521:55-58
  • CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer
    Griffith M, Spies NC, Krysiak K, McMichael JF, Coffman AC, Danos AM, Ainscough BJ, Ramirez CA, Rieke DT, Kujan L, Barnell EK, Wagner AH, Skidmore ZL, Wollam A, Liu CJ, Jones MR, Bilski RL, Lesurf R, Feng YY, Shah NM, Bonakdar M, Trani L, Matlock M, Ramu A, Campbell KM, Spies GC, Graubert AP, Gangavarapu K, Eldred JM, Larson DE, Walker JR, Good BM, Wu C, Su AI, Dienstmann R, Margolin AA, Tamborero D, Lopez-Bigas N, Jones SJ, Bose R, Spencer DH, Wartman LD, Wilson RK, Mardis ER, Griffith OL
    Nat Genet 2017 Jan 31;49(2):170-174
  • Biophysical evidence for intrinsic disorder in the C-terminal tails of the epidermal growth factor receptor (EGFR) and HER3 receptor tyrosine kinases
    Keppel TR, Sarpong K, Murray EM, Monsey J, Zhu J, Bose R
    J Biol Chem 2017 Jan 13;292(2):597-610
  • Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: the NEfERT-T randomized clinical trial
    Awada A, Colomer R, Inoue K, Bondarenko I, Badwe RA, Demetriou G, Lee SC, Mehta AO, Kim SB, Bachelot T, Goswami C, Deo S, Bose R, Wong A, Xu F, Yao B, Bryce R, Carey LA
    JAMA Oncol 2016 Dec 1;2(12):1557-1564
  • [89Zr]trastuzumab: evaluation of radiation dosimetry, safety, and optimal imaging parameters in women with HER2-positive breast cancer
    Laforest R, Lapi SE, Oyama R, Bose R, Tabchy A, Marquez-Nostra BV, Burkemper J, Wright BD, Frye J, Frye S, Siegel BA, Dehdashti F
    Mol Imaging Biol 2016 Dec;18(6):952-959
  • Unsupervised detection of cancer driver mutations with parsimony-guided learning
    Kumar RD, Swamidass SJ, Bose R
    Nat Genet 2016 Oct;48(10):1288-94
  • Prognostic and predictive biomarkers of endocrine responsiveness for estrogen receptor positive breast cancer
    Ma CX, Bose R, Ellis MJ
    Adv Exp Med Biol 2016;882:125-54
  • Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies
    Ross JS, Gay LM, Wang K, Ali SM, Chumsri S, Elvin JA, Bose R, Vergilio JA, Suh J, Yelensky R, Lipson D, Chmielecki J, Waintraub S, Leyland-Jones B, Miller VA, Stephens PJ
    Cancer 2016 Sep 1;122(17):2654-2662
  • Genomic characterization of primary invasive lobular breast cancer
    Desmedt C, Zoppoli G, Gundem G, Pruneri G, Larsimont D, Fornili M, Fumagalli D, Brown D, Rothe F, Vincent D, Kheddoumi N, Rouas G, Majjaj S, Brohee S, Van Loo P, Maisonneuve P, Salgado R, Van Brussel T, Lambrechts D, Bose R, Metzger O, Galant C, Bertucci F, Piccart-Gebhart M, Viale G, Biganzoli E, Campbell PJ, Sotiriou C
    J Clin Oncol 2016 Jun 1;34(16):1872-81
  • HER2-mutated breast cancer responds to treatment with single-agent neratinib, a second-generation HER2/EGFR tyrosine kinase inhibitor
    Ben-Baruch NE, Bose R, Kavuri SM, Ma CX, Ellis MJ
    J Natl Compr Canc Netw 2015 Sep;13(9):1061-4
  • Statistically identifying tumor suppressors and oncogenes from pan-cancer genome-sequencing data
    Kumar RD, Searleman AC, Swamidass SJ, Griffith OL, Bose R
    Bioinformatics 2015 Nov 15;31(22):3561-8
  • HER2 activating mutations are targets for colorectal cancer treatment
    Kavuri SM, Jain N, Galimi F, Cottino F, Leto SM, Migliardi G, Searleman AC, Shen W, Monsey J, Trusolino L, Jacobs SA, Bertotti A, Bose R
    Cancer Discov 2015 Aug;5(8):832-41
  • Analysis of the role of the C-terminal tail in the regulation of the epidermal growth factor receptor
    Kovacs E, Das R, Wang Q, Collier TS, Cantor A, Huang Y, Wong K, Mirza A, Barros T, Grob P, Jura N, Bose R, Kuriyan J
    Mol Cell Biol 2015 Sep 1;35(17):3083-102
  • HER2 missense mutations have distinct effects on oncogenic signaling and migration
    Zabransky DJ, Yankaskas CL, Cochran RL, Wong HY, Croessmann S, Chu D, Kavuri SM, Red Brewer M, Rosen DM, Dalton WB, Cimino-Mathews A, Cravero K, Button B, Kyker-Snowman K, Cidado J, Erlanger B, Parsons HA, Manto KM, Bose R, Lauring J, Arteaga CL, Konstantopoulos K, Park BH
    Proc Natl Acad Sci U S A 2015 Nov 10;112(45):E6205-14
  • Tissue phosphoproteomics with PolyMAC identifies potential therapeutic targets in a transgenic mouse model of HER2 positive breast cancer
    Searleman AC, Iliuk AB, Collier TS, Chodosh LA, Tao WA, Bose R
    Electrophoresis 2014 Apr 10
  • DGIdb: mining the druggable genome
    Griffith M, Griffith OL, Coffman AC, Weible JV, McMichael JF, Spies NC, Koval J, Das I, Callaway MB, Eldred JM, Miller CA, Subramanian J, Govindan R, Kumar RD, Bose R, Ding L, Walker JR, Larson DE, Dooling DJ, Smith SM, Ley TJ, Mardis ER, Wilson RK
    Nat Methods 2013 Dec;10(12):1209-10
  • Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts
    Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, He X, Liu S, Hoog J, Lu C, Ding L, Griffith OL, Miller C, Larson D, Fulton RS, Harrison M, Mooney T, McMichael JF, Luo J, Tao Y, Goncalves R, Schlosberg C, Hiken JF, Saied L, Sanchez C, Giuntoli T, Bumb C, Cooper C, Kitchens RT, Lin A, Phommaly C, Davies SR, Zhang J, Kavuri MS, McEachern D, Dong YY, Ma C, Pluard T, Naughton M, Bose R, Suresh R, McDowell R, Michel L, Aft R, Gillanders W, Deschryver K, Wilson RK, Wang S, Mills GB, Gonzalez-Angulo A, Edwards JR, Maher C, Perou CM, Mardis ER, Ellis MJ
    Cell Rep 2013 Sep 26;4(6):1116-30
  • Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interface
    Collier TS, Diraviyam K, Monsey J, Shen W, Sept D, Bose R
    J Biol Chem 2013 Aug 30;288(35):25254-64
  • Prioritizing potentially druggable mutations with dGene: an annotation tool for cancer genome sequencing data
    Kumar RD, Chang LW, Ellis MJ, Bose R
    PLoS One 2013 Jun 27;8(6):e67980
  • A Neu view of invasive lobular breast cancer
    Bose R
    Clin Cancer Res 2013 Jul 1;19(13):3331-3
  • Using multigene tests to select treatment for early-stage breast cancer
    Goncalves R, Bose R
    J Natl Compr Canc Netw 2013 Feb 1;11(2):174-82; quiz 182
  • Incorporating genomics into breast cancer clinical trials and care
    Tabchy A, Ma CX, Bose R, Ellis MJ
    Clin Cancer Res 2013 Dec 1;19(23):6371-9
  • Activating HER2 mutations in HER2 gene amplification negative breast cancer
    Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, Monsey J, Goel N, Aronson AB, Li S, Ma CX, Ding L, Mardis ER, Ellis MJ
    Cancer Discov 2013 Feb;3(2):224-37
  • Quantitative proteomics with siRNA screening identifies novel mechanisms of trastuzumab resistance in HER2 amplified breast cancers
    Boyer AP, Collier TS, Vidavsky I, Bose R
    Mol Cell Proteomics 2013 Jan;12(1):180-93
  • Comprehensive molecular portraits of human breast tumours
    The Cancer Genome Atlas Network (authors include Bose R)
    Nature 2012 Sep 23;490(7418):61-70
  • Comprehensive genomic characterization of squamous cell lung cancers
    Hammerman PS, Hayes DN, Wilkerson MD, Schultz N, Bose R, Chu A, Collisson EA, Cope L, Creighton CJ, Getz G, Herman JG, Johnson BE, Kucherlapati R, Ladanyi M, Maher CA, Robertson G, Sander C, Shen R, Sinha R, Sivachenko A, Thomas RK, Travis WD, Tsao MS, Weinstein JN, Wigle DA, Baylin SB, Govindan R, Meyerson M
    Nature 2012 Sep 27;489(7417):519-25
  • Genomic landscape of non-small cell lung cancer in smokers and never-smokers
    Govindan R, Ding L, Griffith M, Subramanian J, Dees ND, Kanchi KL, Maher CA, Fulton R, Fulton L, Wallis J, Chen K, Walker J, McDonald S, Bose R, Ornitz D, Xiong D, You M, Dooling DJ, Watson M, Mardis ER, Wilson RK
    Cell 2012 Sep 14;150(6):1121-34
  • Whole-genome analysis informs breast cancer response to aromatase inhibition
    Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, Ng S, Lin L, Crowder R, Snider J, Ballman K, Weber J, Chen K, Koboldt DC, Kandoth C, Schierding WS, McMichael JF, Miller CA, Lu C, Harris CC, McLellan MD, Wendl MC, DeSchryver K, Allred DC, Esserman L, Unzeitig G, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Leitch M, Hunt K, Olson J, Tao Y, Maher CA, Fulton LL, Fulton RS, Harrison M, Oberkfell B, Du F, Demeter R, Vickery TL, Elhammali A, Piwnica-Worms H, McDonald S, Watson M, Dooling DJ, Ota D, Chang LW, Bose R, Ley TJ, Piwnica-Worms D, Stuart JM, Wilson RK, Mardis ER
    Nature 2012 Jun 10;486(7403):353-60
  • Identification of targets of c-src tyrosine kinase by chemical complementation and phosphoproteomics
    Ferrando IM, Chaerkady R, Zhong J, Molina H, Jacob HK, Herbst-Robinson K, Dancy BM, Katju V, Bose R, Zhang J, Pandey A, Cole PA
    Mol Cell Proteomics 2012 Aug;11(8):355-69
  • Carboxyl-group footprinting maps the dimerization interface and phosphorylation-induced conformational changes of a membrane-associated tyrosine kinase
    Zhang H, Shen W, Rempel D, Monsey J, Vidavsky I, Gross ML, Bose R
    Mol Cell Proteomics 2011 Jun;10(6):M110005678
  • Exome sequencing and cis-regulatory mapping identify mutations in MAK, a gene encoding a regulator of ciliary length, as a cause of retinitis pigmentosa
    Ozgul RK, Siemiatkowska AM, Yucel D, Myers CA, Collin RW, Zonneveld MN, Beryozkin A, Banin E, Hoyng CB, van den Born LI, Bose R, Shen W, Sharon D, Cremers FP, Klevering BJ, den Hollander AI, Corbo JC
    Am J Hum Genet 2011 Aug 12;89(2):253-64
  • Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system
    Monsey J, Shen W, Schlesinger P, Bose R
    J Biol Chem 2010 Mar 5;285(10):7035-44
  • The ErbB kinase domain: structural perspectives into kinase activation and inhibition
    Bose R, Zhang X
    Exp Cell Res 2009 Feb 15;315(4):649-58
  • Mechanism of activation and inhibition of the HER4/ErbB4 kinase
    Qiu C, Tarrant MK, Choi SH, Sathyamurthy A, Bose R, Banjade S, Pal A, Bornmann WG, Lemmon MA, Cole PA, Leahy DJ
    Structure 2008 Mar;16(3):460-7
  • Human Proteinpedia enables sharing of human protein data
    Mathivanan S, Ahmed M, Ahn NG, Alexandre H, Amanchy R, Andrews PC, Bader JS, Balgley BM, Bantscheff M, Bennett KL, Bjorling E, Blagoev B, Bose R, et al.
    Nat Biotechnol 2008 Feb;26(2):164-7
  • Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface
    Zhang X, Pickin KA, Bose R, Jura N, Cole PA, Kuriyan J
    Nature 2007 Nov 29;450(7170):741-4
  • Phosphoproteomic analysis of Her2/neu signaling and inhibition
    Bose R, Molina H, Patterson AS, Bitok JK, Periaswamy B, Bader JS, Pandey A, Cole PA
    Proc Natl Acad Sci U S A 2006 Jun 27;103(26):9773-8
  • Protein tyrosine kinase-substrate interactions
    Bose R, Holbert MA, Pickin KA, Cole PA
    Curr Opin Struct Biol 2006 Dec;16(6):668-75
  • Measurement of ceramide levels by the diacylglycerol kinase reaction and by high-performance liquid chromatography-fluorescence spectrometry
    Bose R, Kolesnick R
    Methods Enzymol 2000;322:373-8
  • Measurement of ceramide synthase activity
    Bose R, Kolesnick R
    Methods Enzymol 2000;322:378-82
  • Ceramide generation by the Reaper protein is not blocked by the caspase inhibitor, p35
    Bose R, Chen P, Loconti A, Grullich C, Abrams JM, Kolesnick RN
    J Biol Chem 1998 Oct 30;273(44):28852-9
  • Autoantibodies to DEK oncoprotein in a patient with systemic lupus erythematosus and sarcoidosis
    Dong X, Michelis MA, Wang J, Bose R, DeLange T, Reeves WH
    Arthritis Rheum 1998 Aug;41(8):1505-10
  • Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis
    Verheij M, Bose R, Lin XH, Yao B, Jarvis WD, Grant S, Birrer MJ, Szabo E, Zon LI, Kyriakis JM, Haimovitz-Friedman A, Fuks Z, Kolesnick RN
    Nature 1996 Mar 7;380(6569):75-9
  • Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals
    Bose R, Verheij M, Haimovitz-Friedman A, Scotto K, Fuks Z, Kolesnick R
    Cell 1995 Aug 11;82(3):405-14
  • Overexpression of SIS2, which contains an extremely acidic region, increases the expression of SWI4, CLN1 and CLN2 in sit4 mutants
    Di Como CJ, Bose R, Arndt KT
    Genetics 1995 Jan;139(1):95-107
  • The genes for a mouse hematopoietic differentiation marker called the heat-stable antigen
    Wenger RH, Ayane M, Bose R, Kohler G, Nielsen PJ
    Eur J Immunol 1991 Apr;21(4):1039-46